173 related articles for article (PubMed ID: 38001255)
1. Exploring the genetic and molecular basis of differences in multiple myeloma of individuals of African and European descent.
Levine AJ; Carpten JD; Murphy M; Hainaut P
Cell Death Differ; 2024 Jan; 31(1):1-8. PubMed ID: 38001255
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive molecular profiling of 718 Multiple Myelomas reveals significant differences in mutation frequencies between African and European descent cases.
Manojlovic Z; Christofferson A; Liang WS; Aldrich J; Washington M; Wong S; Rohrer D; Jewell S; Kittles RA; Derome M; Auclair D; Craig DW; Keats J; Carpten JD
PLoS Genet; 2017 Nov; 13(11):e1007087. PubMed ID: 29166413
[TBL] [Abstract][Full Text] [Related]
3. Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients.
Kazandjian D; Hill E; Hultcrantz M; Rustad EH; Yellapantula V; Akhlaghi T; Korde N; Mailankody S; Dew A; Papaemmanuil E; Maric I; Kwok M; Landgren O
Blood Cancer J; 2019 Feb; 9(2):15. PubMed ID: 30718460
[TBL] [Abstract][Full Text] [Related]
4. Common genetic variation in TP53 is associated with lung cancer risk and prognosis in African Americans and somatic mutations in lung tumors.
Mechanic LE; Bowman ED; Welsh JA; Khan MA; Hagiwara N; Enewold L; Shields PG; Burdette L; Chanock S; Harris CC
Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):214-22. PubMed ID: 17301252
[TBL] [Abstract][Full Text] [Related]
5. Tp53 deletion in B lineage cells predisposes mice to lymphomas with oncogenic translocations.
Rowh MA; DeMicco A; Horowitz JE; Yin B; Yang-Iott KS; Fusello AM; Hobeika E; Reth M; Bassing CH
Oncogene; 2011 Nov; 30(47):4757-64. PubMed ID: 21625223
[TBL] [Abstract][Full Text] [Related]
6. Differences in somatic TP53 mutation type in breast tumors by race and receptor status.
Pollock NC; Ramroop JR; Hampel H; Troester MA; Conway K; Hu JJ; Freudenheim JL; Olopade OI; Huo D; Ziv E; Neuhausen SL; Stevens P; McElroy JP; Toland AE
Breast Cancer Res Treat; 2022 Apr; 192(3):639-648. PubMed ID: 35286522
[TBL] [Abstract][Full Text] [Related]
7. Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid.
Hollstein M; Moriya M; Grollman AP; Olivier M
Mutat Res; 2013; 753(1):41-49. PubMed ID: 23422071
[TBL] [Abstract][Full Text] [Related]
8. Prognostic role of TNF alpha, LT alpha, MDR1 and codon 72 Tp53 gene polymorphisms on multiple myeloma Egyptian patients.
Hegazi HM; Elghonemy MS; El-Baiomy MA; Soliman EA; Abdel-Hady EK
Leuk Res; 2022 Jun; 117():106854. PubMed ID: 35594781
[TBL] [Abstract][Full Text] [Related]
9. Prognosis, Biology, and Targeting of
Flynt E; Bisht K; Sridharan V; Ortiz M; Towfic F; Thakurta A
Cells; 2020 Jan; 9(2):. PubMed ID: 31991614
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic deep-targeted next-generation sequencing assessment of TP53 gene mutations in multiple myeloma from the whole bone marrow.
Petrackova A; Minarik J; Sedlarikova L; Libigerova T; Hamplova A; Krhovska P; Balcarkova J; Pika T; Papajik T; Kriegova E
Br J Haematol; 2020 May; 189(4):e122-e125. PubMed ID: 32130732
[No Abstract] [Full Text] [Related]
11. Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma.
Herrero AB; Rojas EA; Misiewicz-Krzeminska I; Krzeminski P; Gutiérrez NC
Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916892
[TBL] [Abstract][Full Text] [Related]
12. TP53 mutations in p53-negative dysplastic urothelial cells from Belgian AAN patients: New evidence for aristolochic acid-induced molecular pathogenesis and carcinogenesis.
Aydin S; Ambroise J; Cosyns JP; Gala JL
Mutat Res Genet Toxicol Environ Mutagen; 2017 Jun; 818():17-26. PubMed ID: 28477877
[TBL] [Abstract][Full Text] [Related]
13. Somatic TP53 Mutations in the Era of Genome Sequencing.
Hainaut P; Pfeifer GP
Cold Spring Harb Perspect Med; 2016 Nov; 6(11):. PubMed ID: 27503997
[TBL] [Abstract][Full Text] [Related]
14. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma.
Lodé L; Eveillard M; Trichet V; Soussi T; Wuillème S; Richebourg S; Magrangeas F; Ifrah N; Campion L; Traullé C; Guilhot F; Caillot D; Marit G; Mathiot C; Facon T; Attal M; Harousseau JL; Moreau P; Minvielle S; Avet-Loiseau H
Haematologica; 2010 Nov; 95(11):1973-6. PubMed ID: 20634494
[TBL] [Abstract][Full Text] [Related]
15. p53 and RAS gene mutations in multiple myeloma.
Portier M; Molès JP; Mazars GR; Jeanteur P; Bataille R; Klein B; Theillet C
Oncogene; 1992 Dec; 7(12):2539-43. PubMed ID: 1461658
[TBL] [Abstract][Full Text] [Related]
16. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
17. p53 tumor suppressor gene status and the degree of genomic instability in sporadic colorectal cancers.
Kahlenberg MS; Stoler DL; Basik M; Petrelli NJ; Rodriguez-Bigas M; Anderson GR
J Natl Cancer Inst; 1996 Nov; 88(22):1665-70. PubMed ID: 8931611
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphisms of multiple DNA repair pathways impact age at diagnosis and TP53 mutations in breast cancer.
Smith TR; Liu-Mares W; Van Emburgh BO; Levine EA; Allen GO; Hill JW; Reis IM; Kresty LA; Pegram MD; Miller MS; Hu JJ
Carcinogenesis; 2011 Sep; 32(9):1354-60. PubMed ID: 21700777
[TBL] [Abstract][Full Text] [Related]
19. Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma.
Voropaeva EN; Pospelova TI; Voevoda MI; Maksimov VN; Orlov YL; Seregina OB
BMC Med Genomics; 2019 Mar; 12(Suppl 2):35. PubMed ID: 30871527
[TBL] [Abstract][Full Text] [Related]
20. Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations.
Kim J; Jeong K; Jun H; Kim K; Bae JM; Song MG; Yi H; Park S; Woo GU; Lee DW; Kim TY; Lee KH; Im SA
Hum Genomics; 2023 Jan; 17(1):2. PubMed ID: 36604691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
